...Bausch + Lomb said that its ISTA Pharmaceuticals Inc. subsidiary will pay about $34 million in civil and... ...in civil and criminal fines to the U.S. government to settle litigation involving conduct by ISTA... ...reimbursement. Bausch + Lomb, which acquired ISTA last June, said it will wind down the ISTA...
...Bausch + Lomb completed its acquisition of fellow ophthalmic company Ista for $9.10 per share in... ...or about $500 million (see BioCentury, April 2). Bausch + Lomb Inc. , Rochester, N.Y. Ista Pharmaceuticals Inc....
...at the Association for Research in Vision and Ophthalmology meeting in Fort Lauderdale. Last month, Ista... ...that Prolensa met the primary and secondary endpoints vs. placebo (see BioCentury, Oct. 17, 2011). Ista... ...acquired by Bausch + Lomb (see BioCentury, April 2). Croma-Pharma GmbH , Leobendorf, Austria Ista Pharmaceuticals Inc. (NASDAQ:ISTA...
...adverse events reported. Patients received twice-daily Beposone, bepotastine, a steroid or placebo for 2 weeks. Ista... ...from Mitsubishi, which markets bepotastine as Talion for allergic rhinitis and urticaria in Japan. Ista Pharmaceuticals Inc. (NASDAQ:ISTA...
...Bausch + Lomb said that its ISTA Pharmaceuticals Inc. subsidiary will pay about $34 million in civil and... ...in civil and criminal fines to the U.S. government to settle litigation involving conduct by ISTA... ...reimbursement. Bausch + Lomb, which acquired ISTA last June, said it will wind down the ISTA...
...Bausch + Lomb completed its acquisition of fellow ophthalmic company Ista for $9.10 per share in... ...or about $500 million (see BioCentury, April 2). Bausch + Lomb Inc. , Rochester, N.Y. Ista Pharmaceuticals Inc....
...at the Association for Research in Vision and Ophthalmology meeting in Fort Lauderdale. Last month, Ista... ...that Prolensa met the primary and secondary endpoints vs. placebo (see BioCentury, Oct. 17, 2011). Ista... ...acquired by Bausch + Lomb (see BioCentury, April 2). Croma-Pharma GmbH , Leobendorf, Austria Ista Pharmaceuticals Inc. (NASDAQ:ISTA...
...adverse events reported. Patients received twice-daily Beposone, bepotastine, a steroid or placebo for 2 weeks. Ista... ...from Mitsubishi, which markets bepotastine as Talion for allergic rhinitis and urticaria in Japan. Ista Pharmaceuticals Inc. (NASDAQ:ISTA...